Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients

Summary Objective Establish a biomarker panel associated with all-cause total joint replacement (TJR) through identification of patients with osteoarthritis (OA) who do or do not progress to TJR and investigate effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Design Serum samples from patients enrolled in phase III trials of tanezumab who experienced TJR ( n = 174) or matched patients who did not ( n = 321) were analyzed for bone, cartilage, soft tissue, and inflammation markers. Classification and Regression Tree (CART) analysis was used to identify biomarker phenotypes associated with TJR. Results At baseline, biomarker combinations for patients who did not use NSAIDs before starting tanezumab and used NSAIDs during tanezumab treatment